The goal of Project 3 is for Crucell to vial, release, and manage clinical-grade Ad26 vectors expressing HlV-1 mosaic Env/Gag/Pol antigens and our stable clade C HlV-1 Env gp140 trimer for the phase 1 studies described in Project 2 as well as for potential future phase 2a/2b clinical studies. As part of our ongoing IPCAVD A1078526 program, we are currently manufacturing multivalent Ad26 vectors expressing mosaic Env/Gag/Pol antigens as well as our stable clade C gp140 trimer under GMP conditions for clinical trials. Sufficient bulk material will be manufactured to support both phase 1 and phase 2a/2b clinical trials. However, our IPCAVD AI078526 program will end in 2013, and thus we would require this new IPCAVD grant to develop these novel HlV-1 vaccine candidates further. In this project, Crucell will fill and release the remainder of the Ad26 drug substance and the HIV-1 Env gp140 trimer to support the phase 1 studies described in Project 2 and for potential future phase 2a/2b clinical studies. Crucell will also provide all the regulatory and project management support required for this IPCAVD program. To accomplish these goals, we propose the following three Specific Aims: 1. To vial, release, and monitor stability of clinical-grade Ad26 vectors expressing HlV-1 mosaic Env/Gag/Pol antigens under GMP conditions; 2. To vial, release, and monitor stability of clinical-grade HlV-1 Env gp140 trimer under GMP conditions;and 3. To provide the regulatory and project management support required for this IPCAVD program.
Manufacturing and regulatory support of GMP-grade vaccine products are critical for the development of an HlV-1 vaccine. In this Project, Crucell will provide the product, regulatory, and project management support required forthis IPCAVD program.
|Stephenson, Kathryn E; Neubauer, George H; Reimer, Ulf et al. (2015) Quantification of the epitope diversity of HIV-1-specific binding antibodies by peptide microarrays for global HIV-1 vaccine development. J Immunol Methods 416:105-23|
|Baden, Lindsey R; Liu, Jinyan; Li, Hualin et al. (2015) Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans. J Infect Dis 211:518-28|
|Barouch, Dan H; Picker, Louis J (2014) Novel vaccine vectors for HIV-1. Nat Rev Microbiol 12:765-71|
|Dugast, Anne-Sophie; Chan, Ying; Hoffner, Michelle et al. (2014) Lack of protection following passive transfer of polyclonal highly functional low-dose non-neutralizing antibodies. PLoS One 9:e97229|
|Balandya, Emmanuel; Miller, Andrew D; Beck, Matthew et al. (2014) Adenovirus serotype 26 and 35 vectors induce simian immunodeficiency virus-specific T lymphocyte responses in foreskin in rhesus monkeys. J Virol 88:3756-65|
|Barouch, Dan H; Michael, Nelson L (2014) Accelerating HIV-1 Vaccine Efficacy Trials. Cell 159:969-72|
|Penaloza-MacMaster, Pablo; Teigler, Jeffrey E; Obeng, Rebecca C et al. (2014) Augmented replicative capacity of the boosting antigen improves the protective efficacy of heterologous prime-boost vaccine regimens. J Virol 88:6243-54|
|Nkolola, Joseph P; Bricault, Christine A; Cheung, Ann et al. (2014) Characterization and immunogenicity of a novel mosaic M HIV-1 gp140 trimer. J Virol 88:9538-52|
|Baden, Lindsey R; Walsh, Stephen R; Seaman, Michael S et al. (2014) First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002). J Infect Dis 210:1052-61|
|Whitney, James B; Hill, Alison L; Sanisetty, Srisowmya et al. (2014) Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature 512:74-7|
Showing the most recent 10 out of 26 publications